498.34
8.86 (1.81%)
| Previous Close | 489.48 |
| Open | 481.36 |
| Volume | 284,409 |
| Avg. Volume (3M) | 343,696 |
| Market Cap | 14,143,528,960 |
| Price / Earnings (TTM) | 32.66 |
| Price / Earnings (Forward) | 29.15 |
| Price / Sales | 5.82 |
| Price / Book | 30.82 |
| 52 Weeks Range | |
| Earnings Date | 22 Apr 2026 |
| Profit Margin | 19.31% |
| Operating Margin (TTM) | 20.32% |
| Diluted EPS (TTM) | 13.10 |
| Quarterly Revenue Growth (YOY) | 9.30% |
| Quarterly Earnings Growth (YOY) | 11.70% |
| Total Debt/Equity (MRQ) | 25.33% |
| Current Ratio (MRQ) | 0.730 |
| Operating Cash Flow (TTM) | 581.97 M |
| Levered Free Cash Flow (TTM) | 433.28 M |
| Return on Assets (TTM) | 15.44% |
| Return on Equity (TTM) | 65.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Medpace Holdings, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 3.0 |
| Average | 2.38 |
|
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Growth |
| % Held by Insiders | 20.55% |
| % Held by Institutions | 91.47% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 560.00 (Jefferies, 12.37%) | Buy |
| Median | 511.00 (2.54%) | |
| Low | 419.00 (TD Cowen, -15.92%) | Hold |
| Average | 504.17 (1.17%) | |
| Total | 2 Buy, 4 Hold | |
| Avg. Price @ Call | 443.01 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 06 Mar 2026 | 500.00 (0.33%) | Hold | 470.59 |
| 11 Feb 2026 | 500.00 (0.33%) | Sell | 423.93 | |
| RBC Capital | 03 Mar 2026 | 522.00 (4.75%) | Buy | 465.38 |
| TD Cowen | 18 Feb 2026 | 419.00 (-15.92%) | Hold | 446.17 |
| Jefferies | 13 Feb 2026 | 560.00 (12.37%) | Buy | 428.03 |
| Leerink Partners | 11 Feb 2026 | 485.00 (-2.68%) | Hold | 423.93 |
| Truist Securities | 11 Feb 2026 | 539.00 (8.16%) | Hold | 423.93 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CARLEY BRIAN T | - | - | 0 | 0 |
| KRAFT ROBERT O. | - | - | 0 | 0 |
| MCCARTHY CORNELIUS P. III | - | - | 0 | 0 |
| Aggregate Net Quantity | 0 | |||
| Aggregate Net Value ($) | 0 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| CARLEY BRIAN T | Director | 31 Mar 2026 | Option execute | 36 | - | - |
| KRAFT ROBERT O. | Director | 31 Mar 2026 | Option execute | 33 | - | - |
| MCCARTHY CORNELIUS P. III | Director | 31 Mar 2026 | Option execute | 29 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |